Florence Vonmoos, Ph.D.

Dr. Florence Vonmoos joined PMI in 2006 as scientist in Toxicological Product Assessment. Since then, she has been directly involved in the toxicological risk assessment of ingredients, materials, prototypes and finished products, including e-liquid formulations and ENDS. She is currently the key subject matter expert formulating assessment strategies for smoke-free products, leveraging novel approach methodologies such as in silico tools and exploratory empirical data to elevate current approaches to next-generation risk assessment. With long-term experience in pre-clinical assessment of smoke-free products, Dr. Vonmoos is actively contributing to vaping product standards as a member of three working groups of the European Committee for Standardization for Vaping Products (CEN TC 437). In addition, Dr. Vonmoos lends her expertise and scientific guidance to the company's efforts to substantiate tobacco harm reduction claims for smoke-free products.

Dr. Vonmoos holds a Ph. D. in Molecular Biology from the University of Geneva in Switzerland and is a member of the Swiss Toxicology Society.